Last updated on July 2019

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer


Brief description of study

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

Clinical Study Identifier: NCT03148795

Find a site near you

Start Over

Icon Cancer Care South Brisbane

South Brisbane, Australia
6.32miles
  Connect »

Ion Cancer Care

South Brisbane, Australia
6.32miles
  Connect »

Icon Cancer Care Wesley

Auchenflower, Australia
6.61miles
  Connect »

River City Pharmacy

Auchenflower, Australia
6.61miles
  Connect »